Education
About Us
Working with TipRanks
Follow Us
Oramed Pharmaceuticals (ORMP)
NASDAQ:ORMP
Total Valuation
Oramed Pharm has a market cap or net worth of $86.19M. The enterprise value is -$23.59M.
Market Cap$86.19M
Enterprise Value-$23.59M
Share Statistics
Oramed Pharm has 40.85M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding40.85M
Owned by Insiders13.16%
Owned by Instutions15.34%
Financial Efficiency
Oramed Pharm’s return on equity (ROE) is 0.03 and return on invested capital (ROIC) is -7.21%.
Return on Equity (ROE)3.37%
Return on Assets (ROA)2.51%
Return on Invested Capital (ROIC)-7.21%
Return on Capital Employed (ROCE)-9.42%
Revenue Per Employee$0
Profits Per Employee$343,461.538
Employee Count13
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Oramed Pharm is 16.86. Oramed Pharm’s PEG ratio is -0.15.
PE Ratio16.86
PS Ratio69.50
PB Ratio0.57
Price to Fair Value0.57
Price to FCF-8.83
Price to Operating Cash Flow-9.05
PEG Ratio-0.15
Income Statement
In the last 12 months, Oramed Pharm had revenue of $0.00 and earned $4.46M in profits. Earnings per share was -$0.22.
Revenue$0.00
Gross Profit$0.00
Operating Income-$13.06M
Pretax Income$7.16M
Net Income$4.46M
EBITDA24.86M
Earnings Per Share (EPS)-0.22
Cash Flow
In the last 12 months, operating cash flow was -$7.92M and capital expenditures -$10.00K, giving a free cash flow of -$7.93M billion.
Operating Cash Flow-$7.92M
Free Cash Flow-$7.93M
Free Cash Flow per Share-$0.19
Dividends & Yields
Oramed Pharm pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-11.33%
Earnings Yield5.93%
Stock Price Statistics
Beta0.93
52-Week Price Change-6.20%
50-Day Moving Average2.26
200-Day Moving Average2.37
Relative Strength Index (RSI)41.55
Average Volume (3m)118.22K
Important Dates
Oramed Pharm upcoming earnings date is Jul 10, 2024, TBA.
Last Earnings DateJan 11, 2024
Next Earnings DateJul 10, 2024
Ex-Dividend Date―
Financial Position
Oramed Pharm as a current ratio of 3.06, with Debt / Equity ratio of 0.32
Current Ratio3.06
Quick Ratio3.06
Debt to Market Cap0.55
Net Debt to EBITDA-2.73
Interest Coverage Ratio-4.40
Taxes
In the past 12 months, Oramed Pharm has paid $2.77M in taxes.
Income Tax$2.77M
Effective Tax Rate0.00%
Enterprise Valuation
Oramed Pharm EV to EBITDA ratio is -8.71, with an EV/FCF ratio of -12.86.
EV to Sales101.26
EV to EBITDA-8.71
EV to Free Cash Flow-12.86
EV to Operating Cash Flow-13.18
Balance Sheet
Oramed Pharm has $142.30M in cash and marketable securities with $429.00K in debt, giving a net cash position of -$141.87M billion.
Cash & Marketable Securities$142.30M
Total Debt$429.00K
Net Cash-$141.87M
Net Cash Per Share-$3.47
Tangible Book Value Per Share$4.04
Margins
Gross margin is 100.00%, with operating margin of -1176.79%, and net profit margin of 412.31%.
Gross Margin100.00%
Operating Margin-1176.79%
Pretax Margin379.70%
Net Profit Margin412.31%
EBITDA Margin-1162.16%
EBIT Margin531.72%
Analyst Forecast
The average price target for Oramed Pharm is , which is 11.43% higher than the current price. The consensus rating is
Price Target
Price Target Upside
Analyst Consensus
Analyst Count0
Revenue Growth Forecast-100.00%
EPS Growth Forecast